zilovertamab,ibrutinib
oncternal therapeutics,janssen,abbvie,merck
['zilovertamab', 'ibru', 'oncternal', '$onct']
$onct oncternal therapeutics presents rationale and plans for its registrational phase 3 study evaluating zilovertamab in combination with ibrutinib at the eha 2022 congress stock news alerts in bio
Over 500 members. DM us for our premium stock alerts.